Onconetix, Inc. Files 8-K: Agreements, Financial Obligations, and Personnel Changes

Ticker: ONCO · Form: 8-K · Filed: 2025-02-18T00:00:00.000Z

Sentiment: neutral

Topics: agreement, financial-obligation, accounting-change, personnel-change

Related Tickers: ONCO

TL;DR

Onconetix (ONCO) filed an 8-K detailing new financial obligations and accounting changes.

AI Summary

Onconetix, Inc. (formerly Blue Water Biotech, Inc.) announced on February 12, 2025, a material definitive agreement and a direct financial obligation. The company also reported changes in its certifying accountant and updates regarding its directors and officers, including compensatory arrangements.

Why It Matters

This 8-K filing indicates significant corporate actions including new financial commitments and changes in accounting oversight, which could impact the company's financial health and strategic direction.

Risk Assessment

Risk Level: medium — The filing involves material definitive agreements and financial obligations, which carry inherent risks related to execution and financial performance.

Key Players & Entities

FAQ

What is the nature of the material definitive agreement Onconetix, Inc. entered into?

The filing indicates a "Material Definitive Agreement" was entered into, but the specific details of this agreement are not provided in the summary information.

What is the direct financial obligation reported by Onconetix, Inc.?

The filing states "Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant," but the specific details of the obligation are not detailed in the provided text.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing was on February 12, 2025.

What were Onconetix, Inc.'s former names?

Onconetix, Inc. was formerly known as Blue Water Biotech, Inc. and Blue Water Vaccines Inc.

What are the key items reported in this 8-K filing?

The key items reported are: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Changes in Registrant's Certifying Accountant, and Changes in Registrant's Directors and Officers, along with Compensatory Arrangements and Financial Statements/Exhibits.

From the Filing

0001213900-25-014928.txt : 20250218 0001213900-25-014928.hdr.sgml : 20250218 20250218165854 ACCESSION NUMBER: 0001213900-25-014928 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250212 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Changes in Registrant's Certifying Accountant ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250218 DATE AS OF CHANGE: 20250218 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Onconetix, Inc. CENTRAL INDEX KEY: 0001782107 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41294 FILM NUMBER: 25635920 BUSINESS ADDRESS: STREET 1: 201 E. FIFTH STREET STREET 2: SUITE 1900 CITY: CINCINNATI STATE: OH ZIP: 45202 BUSINESS PHONE: 513-620-4101 MAIL ADDRESS: STREET 1: 201 E. FIFTH STREET STREET 2: SUITE 1900 CITY: CINCINNATI STATE: OH ZIP: 45202 FORMER COMPANY: FORMER CONFORMED NAME: Blue Water Biotech, Inc. DATE OF NAME CHANGE: 20230424 FORMER COMPANY: FORMER CONFORMED NAME: Blue Water Vaccines Inc. DATE OF NAME CHANGE: 20190710 8-K 1 ea0231345-8k_onconetix.htm CURRENT REPORT false 0001782107 0001782107 2025-02-12 2025-02-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): February 12, 2025   Onconetix, Inc. (Exact name of registrant as specified in its charter)   Delaware   001-41294   83-2262816 (State or other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)   201 E. Fifth Street , Suite 1900 Cincinnati , Ohio   45202 (Address of Principal Executive Offices)   (Zip Code)   Registrant’s telephone number, including area code: ( 513 ) 620-4101   (Former name or former address, if changed since last report.)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of Each Class   Trading Symbol(s)   Name of Each Exchange on Which Registered Common Stock, par value $0.00001 per share   ONCO   The Nasdaq Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐             Item 1.01. Entry Into a Ma

View on Read The Filing